GOG GYN-LIVE podcast

GOG-3101 | TroFuse-20 Clinical Trial Update

3/5/2026
0:00
13:00
Rewind 15 seconds
Fast Forward 15 seconds

In this episode, we dive into GOG‑3101 TroFuse‑20—a Phase 3, randomized, active‑controlled, open‑label, multicenter study evaluating MK‑2870 monotherapy versus Treatment of Physician’s Choice as second‑ or third‑line therapy for patients with recurrent or metastatic cervical cancer.

★ Support this podcast ★

More episodes from "GOG GYN-LIVE"